Jessica Foglesong is Joining Miltenyi Biomedicine as a Clinical Development Medical Director
Jessica Foglesong, Clinical Development Medical Director at Miltenyi Biomedicine, shared a post on LinkedIn:
“I’m excited to share that next week marks the beginning of a new professional chapter as I join Miltenyi Biomedicine as a Clinical Development Medical Director!
I’m especially excited to be making this transition into biotech – a field where I can continue to grow, learn from brilliant colleagues, and hopefully contribute in meaningful ways. I’m looking forward to understanding the strengths of my team and identifying where my clinical and regulatory experiences can add value.
Miltenyi Biomedicine is advancing innovative cell and gene therapies that not only push the boundaries of science, but also aim to address accessibility – a critical issue in cancer care and regenerative medicine.
I’m deeply grateful for the opportunity to join a mission-driven team committed to improving the lives of patients with serious diseases.
A heartfelt thank you to everyone who reached out, took time to speak with me, and helped me find the right fit for this next chapter. Your support and generosity made all the difference.”
More posts featuring Miltenyi Biomedicine.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023